Drugs / SER150
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04881123 | Aug 2021 → Jun 2024 | diabetic kidney disease | Serodus AS | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-03-05 | Serodus AS | Regulatory 2021-03 – Announcement Release SER150 CL-009 Approval EC Australia serodus.com ↗
Serodus ASA, the biotech company who focus on treatment of patients suffering from diabetic kidney disease today announced that the next clinical study with the lead compound SER150 has been approved by Australian Ethical Committee 1st March 2021. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-10-24 | Serodus AS | 2022-10 – European Patent office has Published a SER150 patent 19th October 2022 serodus.com ↗ |
| 2021-03-05 | Serodus AS | 2021-03 – Announcement Release SER150 CL-009 Approval EC Australia serodus.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SER150 | “Randomized participants will receive SER150, 15 mg, orally, BID (except on Day 168 where participants will only receive a 15 mg single dose (QD) in the morning)” NCT04881123 ↗ |
| Route | Oral | “Randomized participants will receive SER150, 15 mg, orally, BID (except on Day 168 where participants will only receive a 15 mg single dose (QD) in the morning)” NCT04881123 ↗ |